Press release
Renal Anemia Treatment Market By Top Key Players- Keryx Biopharmaceuticals, Alaven pharmaceutical LLC, Contract Pharmacal, and Amgen
Anemia is a condition in which red blood cells carry less oxygen to tissues and organs, particularly the heart and brain. Based on etiology, anemia can be grouped into three categories: decreased RBC production, increased RBC destruction, and blood loss. Anemia commonly occurs in patients with chronic kidney disease (CKD). When kidneys are damaged, they do not produce enough erythropoietin. As a result, the bone marrow does not produce enough red blood cells, causing anemia. The common causes of renal anemia include blood loss from hemodialysis; low levels of iron, vitamin B12, and folic acid; bone marrow problems, chronic infections, and malnutrition. Renal anemia can be diagnosed through an examination of medical history, physical examination, and blood tests.
Get Free Sample Copy Of This Report @ https://www.marketresearchreports.biz/sample/sample/6697
According to National Health and Nutrition Examination Survey (NHANES) III study, anemia is twice as prevalent in people with chronic kidney disease (15.4%) than in the general population (7.6%). Treatment for renal anemia patients begins with oral iron, graduating to IV iron, and erythropoietin-stimulating agents (ESA). In addition to this, recently launched new therapies include Mircera, erythropoietin-stimulating agent biosimilar, and auryxia. Mircera is a methoxy polyethylene glycol-epoetin beta. It received FDA approval in 2007 and is marketed by Roche in Europe. Despite receiving FDA approval , Mircera had never launched in the U.S. due to a settlement agreement under which Roche agreed to delay the launch until mid-2014. However, in 2015, Roche entered into an exclusive license agreement for the commercialization of Mircera in the U.S. with Galenica AG. In December 2014, Keryx Biopharmaceuticals, Inc. launched Auryxia (ferric citrate) in the U.S. Auryxia (ferric citrate) is the first phosphate binder used to treat elevated phosphate levels in renal anemia.
Rise in prevalence of chronic kidney diseases and high unmet need for drugs that can effectively and safely control the diseases are projected to drive the global renal anemia market during the forecast period. Additionally, launching of new drugs such as prolyl hydroxylase (HIF-PH) inhibitors and erythropoiesis-stimulating agent biosimilars is anticipated to drive the global renal anemia market in the near future. However, adverse effects and high costs of drugs are likely to restrain the global renal anemia treatment market.
The global renal anemia treatment market can be segmented based on treatment, route of administration, distribution channel, and region. In terms of treatment, the global renal anemia treatment market can be categorized into iron supplement, erythropoietin, red blood cell transfusions, and vitamin B12 and folic acid supplements. Based on route of administration, the global renal anemia market can be bifurcated into oral and injectable. In terms of distribution channel, the global renal anemia treatment market can be divided into online pharmacies, retail pharmacies, and hospital pharmacies.
Based on region, the global renal anemia treatment market can be segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is expected to account for a significant share of the global market in 2017 due to high prevalence of chronic kidney diseases in the region. According to the National Chronic Kidney Disease fact sheet, in 2017, 30 million people or 15% of U.S. adults had CKD. Moreover, launch of novel therapies and well established health care infrastructure are expected to drive the market in the region during forecast period. The market share of Europe is expected to decline in the coming years due to change in reimbursement guidelines and competition from biosimilars. The renal anemia treatment market in Asia Pacific is expected to expand rapidly during the forecast period. Expansion of the market in the region can be attributed to a rise in prevalence of chronic kidney diseases and better access to health care.
Request For TOC @ https://www.marketresearchreports.biz/sample/toc/6697
Key players operating in the global renal anemia treatment market are Keryx Biopharmaceuticals, Inc. Alaven pharmaceutical LLC, Contract Pharmacal Corp., and Amgen Inc.
MRR.BIZ has been compiled in-depth market research data in the report after exhaustive primary and secondary research. Our team of able, experienced in-house analysts has collated the information through personal interviews and study of industry databases, journals, and reputable paid sources.
The report provides the following information:
Tailwinds and headwinds molding the market’s trajectory
Market segments based on products, technology, and applications
Prospects of each segment
Overall current and possible future size of the market
Growth pace of the market
Competitive landscape and key players’ strategies
The main aim of the report is to:
Enable key stakeholder’s in the market bet right on it
Understand the opportunities and pitfalls awaiting them
Assess the overall growth scope in the near term
Strategize effectively with respect to production and distribution
MRR.BIZ is a leading provider of strategic market research. Our vast repository consists research reports, data books, company profiles, and regional market data sheets. We regularly update the data and analysis of a wide-ranging products and services around the world. As readers, you will have access to the latest information on almost 300 industries and their sub-segments. Both large Fortune 500 companies and SMEs have found those useful. This is because we customize our offerings keeping in mind the specific requirements of our clients.
About Us
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact Us
Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Renal Anemia Treatment Market By Top Key Players- Keryx Biopharmaceuticals, Alaven pharmaceutical LLC, Contract Pharmacal, and Amgen here
News-ID: 1759254 • Views: …
More Releases from Renal Anemia Treatment Market
Renal Anemia Treatment Market to Benefit from Rapid Technological Advancements D …
Increasing prevalence of chronic kidney diseases is generating a substantial demand for renal anemia treatment. As per the latest research study published by Trends Market research, the renal anemia treatment market was valued at US$ XX Mn in 2017 and is likely to carry promising aspects over the assessment period. The research report on renal anemia treatment market also estimates that the market will grow at a y-o-y of over…
More Releases for Keryx
Chronic Kidney Disease Drugs Market Insights by 2027 & Covid-19 Analysis | Amgen …
The most successful and fruitful entrepreneurs in the worldwide market are objectively assessed. It also addresses the situation that are causing the market to slow things down. Here, the constraints, restraints and tasks that corporations will face are also addressed in high level. The visible usage, supply, and import specialist of manufacturing systems in India, Europe, China, North America, Southeast Asia, and Japan are described in this Chronic Kidney Disease…
Kidney desease Market Report 2021 Clinical Aspect | Sanofi,Amgen,Teva Pharmaceut …
“Kidney Disease market” Research analyses the market is growing with the healthy CAGR in the above-mentioned research forecast period. Rising prevalence of serious kidney problems worldwide and emerging markets are the factors responsible for the growth of this market.
The report will provide details about Kidney desease used in the treatment of Kidney desease and how the market has been influenced by the pandemic of COVID-19. This report will also highlight…
Deficiency Anemia Market Size Analysis, Industry Outlook, Regional Forecast 2021 …
Iron-deficiency Anemia is a common type of anaemia caused by a lack of iron in the body. Anemia is a disorder characterised by a lack of healthy red blood cells. RBCs (red blood cells) transport oxygen throughout the body. Iron is essential for the production of haemoglobin, which is a component of red blood cells. Hemoglobin deficiency implies a lack of oxygen in the body. As a result, maintaining iron…
Emerging Trends of Renal Anemia Treatment Market 2020-2028 with Contract Pharmac …
Renal anemia is a condition that develops from a lower count of healthy red blood cells in the body. Generally, in case of anemia, the red blood cells in the body carry less oxygen to organs and tissues. In such condition, mainly brain and heart lacks from adequate supply of oxygen. Anemic patients mostly suffer from chronic kidney disease, which further leads them in receiving renal replacement therapy. Renal anemia…
Global Ferric Citrate Market 2018 Trend and Outlook - Keryx, Panion & BF Biotech …
The Market Research Study titled 2018-2023 Global Ferric Citrate Consumption Market Report delivers a comprehensive research based study of the Ferric Citrate market, specializing in current industry updates. The report reveals the market share, size, dynamics, forecast data, and detailed overview of the industry with respect to global market. Then the report emphasizes on driver and restraint factors in the global and regional level.
The report studies the historical and present performance…
Hyperphosphatemia Drugs Market Leading Manufacturers Like Keryx Biopharmaceutica …
Increasing launches and approval of novel drugs in key regions are expected to fuel the global hyperphosphatemia drugs market growth in near future. For instance, in 2016, Astellas Pharma Inc. received marketing approval for its Kiklin Granules 86.2%, indicated for the treatment of hyperphosphatemia in patients with chronic kidney disease in Japan. In 2015, Keryx Biopharmaceuticals, Inc. received approval from European Commission for new drug Fexeric (R) (ferric citrate coordination…
